about
Clinical utilities and biological characteristics of melanoma sentinel lymph nodesUpdate and Review on the Surgical Management of Primary Cutaneous MelanomaState of melanoma: an historic overview of a field in transition.Dramatic innovations in modern surgical subspecialtiesMultimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.Staging and prognosis of cutaneous melanoma.Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.Thick primary melanoma has a heterogeneous tumor biology: an institutional seriesAssociation of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database.Interval sentinel lymph nodes: an unusual localization in patients with cutaneous melanoma.Invasive mucinous carcinoma arising in ectopic axillary breast tissue: a case report and literature review.Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisaShould sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers?Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinomaJoint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinomaFinal Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node BiMetastatic melanoma in the older patient: immunologic insights and treatment outcomes.Current and planned multicenter trials for patients with primary or metastatic melanoma.Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis.Skin Cancers in Organ Transplant Recipients.Diversity of stage III melanoma in the era of sentinel lymph node biopsy.Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma.Sentinel lymph node biopsy status is not the most powerful predictor of prognosis in cutaneous melanoma.Melanoma Patient-Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial.Impact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients.Clinicopathologic Factors Predictive of Occult Lymph Node Involvement in Cutaneous Head and Neck Melanoma.Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread--results of a large prospective trial.Stratifying SLN incidence in intermediate thickness melanoma patients.
P2860
Q26747723-5B64A1E2-7FBC-486F-947E-0A3DC8D233DEQ26851966-3CBBB72A-2DCA-490B-BA42-EAFB5A3834E2Q33693906-1B10A766-C786-475F-A21F-2C5187AC600AQ34161700-383D04A2-3B02-462D-AF48-5F6E0325C49EQ34372934-05D86E19-D64F-45FE-BCC0-9166A3ED7FA5Q34625447-3DA23BF1-E544-45A2-9E50-C5F87684C2AAQ34640145-4B611143-5345-47E0-857C-52047CE9FB1AQ34957433-0E0F45EF-2F6C-4A96-8425-BF4E5290EB13Q34958225-B2C50FC1-356A-4C3B-843F-2A8D3D0D3488Q35089936-46CC3B76-7B12-4B2B-A905-DCEC6A40A9ACQ35208703-0BCEDD6F-7670-4693-8B6B-C9D162361520Q35624171-B6EBB254-E303-49C8-9570-AE9BD5914DC9Q36304025-C941D45C-EEFC-46D3-928A-343A9BBE798CQ36365458-730EDCB2-177B-4268-8223-1DA7838E8E8EQ36532123-532C739C-0DC5-413E-A581-7DE4AA873042Q37375980-39536111-A15F-492E-88E9-FD9C1E4082BEQ37392582-B6FAB770-CF61-412B-B040-2F79FED6CE89Q37397750-04D09555-0D9B-42B4-8EDD-199B25A2D523Q37659032-24A17609-18EA-4851-B0E9-3F8C665C7198Q37863112-BF773A6A-D4C4-4180-9413-B628A6AB5A34Q37920844-9203F370-7A3A-44C1-B483-4CB5EA2798A6Q38757160-58FCEE02-8266-4E63-ACEA-DD08E36A2673Q39337780-A744C15F-ED71-4628-B8AE-4BEA08FA8D32Q44714604-DE034DC3-8240-4F18-98A5-C77C81193597Q45130708-189DE792-125E-4942-95E0-A05896AFF3FEQ46125923-07C12643-6358-4958-AB67-ADEAA10B374BQ46136921-BE5BEE07-DEC5-46EB-BFE4-D15F94C556FCQ47731453-6AE35A6D-03F8-48DE-A7C7-914EDE6C2C15Q47862422-19BBA6F0-9396-4D97-A272-5B70D2BF6414Q48369437-C693F2C4-B142-4275-8678-C7E89C329905Q50122047-077FC749-453D-4AA1-AC8A-8F066DFCF8BAQ52885012-BCAD57E8-CD25-4252-BEF6-C8C5BB62F4CBQ55055777-5D140AF9-5694-4F0D-BAAA-3D108BDF14BF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Lessons learned from the Sunbelt Melanoma Trial.
@en
type
label
Lessons learned from the Sunbelt Melanoma Trial.
@en
prefLabel
Lessons learned from the Sunbelt Melanoma Trial.
@en
P2093
P356
P1476
Lessons learned from the Sunbelt Melanoma Trial.
@en
P2093
B Scott Davidson
Douglas S Reintgen
James S Goydos
Jeffrey E Gershenwald
Jeffrey J Sussman
Kelly M McMasters
Merrick I Ross
Peter D Beitsch
R Dirk Noyes
Sunbelt Melanoma Trial
P304
P356
10.1002/JSO.20084
P577
2004-07-01T00:00:00Z